XFLT: Reverse Split Didn't Fix Structural Issues
Finance

XFLT: Reverse Split Didn't Fix Structural Issues

authorBy Mariana Mazzucato
DateMay 20, 2026
Read time2 min

Debt-focused investments continue to struggle in a high-interest-rate environment. Many sectors, including business development companies, REITs, and various income funds, have seen their valuations decline. Unfortunately, the XAI Octagon Floating Rate & Alternative Income Trust (XFLT) is no exception, exhibiting ongoing Net Asset Value (NAV) erosion and fundamental weaknesses that a reverse stock split has not resolved.

Despite its attractive 14.1% yield, XFLT trades at a significant discount of approximately 19% to its NAV, reflecting investor concerns about its performance and inherent risks. The fund's aggressive leverage, maintaining a 39% ratio, coupled with limited transparency regarding credit quality and substantial exposure to volatile market segments, raises red flags for potential investors. These factors suggest that the fund's structural issues are deep-rooted and not easily remedied.

The outlook for XFLT remains challenging if interest rates persist at current levels or continue to climb. The opportunity cost of investing in XFLT versus more stable and transparent alternatives, such as the actively managed exchange-traded fund BIZD, is considerable. Given these concerns, a cautious approach and a 'sell' recommendation are warranted for XFLT, urging investors to seek more resilient options in the current economic climate.

Investing wisely means not only seeking high returns but also understanding and mitigating risks. It's crucial to prioritize transparency, assess leverage, and consider the broader economic landscape to make informed decisions that align with long-term financial well-being. By focusing on fundamental strength and diversification, investors can navigate volatile markets with greater confidence and secure a more stable financial future.

More Articles
Finance
General Mills' Strategic Resilience Amidst Inflationary Pressures
General Mills (GIS) faces scrutiny as its stock's previous sharp decline reflects concerns over diminishing volumes and margin compression. However, the food giant's potential for recovery lies in its ability to navigate persistent inflation, transforming rising costs into profitable pricing strategies rather than sustained financial strain. While signs of improvement in market penetration and pricing dynamics offer a glimmer of hope, concrete evidence of margin stability is crucial for General Mills to become an attractive investment, despite its enticing dividend yield.
By Michele FerreroMay 20, 2026
Finance
Global Equity Market Shifts: Rebalancing for Returns
Recent changes in global equity markets necessitate a re-evaluation of investment strategies. Over the past 16 months, emerging markets and European stocks have significantly outperformed, with emerging markets surging by 53.8% and European stocks by 42.2%. Given the current high valuations and concentration in the US market, investors should consider diversifying their portfolios to include value equities, non-US developed markets, and emerging markets to capture broader return potential.
By Mariana MazzucatoMay 20, 2026
Finance
Philips: AI Integration and Margin Expansion Drive Investment Appeal
Philips is demonstrating strong earnings growth through productivity initiatives, cost control, and strategic portfolio changes. The company's vast installed base and proprietary healthcare data position it to excel in AI-powered healthcare solutions. Following a robust Q1 performance and an anticipated recovery in the EU MedTech sector, Philips presents an attractive investment opportunity for both earnings growth and multiple expansion.
By Lisa JingMay 20, 2026
Finance
Novo Nordisk: A Deep Value Opportunity in the Pharmaceutical Sector
This article evaluates Novo Nordisk (NVO) as a 'Buy' opportunity following a significant market correction. Despite recent setbacks, its robust pipeline, including advanced GLP-1 treatments, positions it favorably against competitors like Eli Lilly. The analysis suggests a stable revenue outlook and potential for substantial annualized returns through 2030, highlighting that current market pessimism overlooks NVO's long-term prospects. However, it also acknowledges risks from clinical failures and pricing pressures.
By Michele FerreroMay 20, 2026
Finance
UK Inflation's Dip: Rethinking Rate Hikes
Recent inflation data from the UK, showing a decrease below 3% in April, suggests that aggressive interest rate hikes by the Bank of England may not be necessary. This new information, coupled with earlier job market figures, challenges the market's current expectations for tighter monetary policy, indicating that the impact of past food price surges on broader inflation might be less severe than anticipated.
By Robert KiyosakiMay 20, 2026